137 related articles for article (PubMed ID: 30099489)
1. Immunotherapy With Apitopes Blocks the Immune Response to TSH Receptor in HLA-DR Transgenic Mice.
Jansson L; Vrolix K; Jahraus A; Martin KF; Wraith DC
Endocrinology; 2018 Sep; 159(9):3446-3457. PubMed ID: 30099489
[TBL] [Abstract][Full Text] [Related]
2. Thyrotropin Receptor-Specific Lymphocytes in Adenovirus-TSHR-Immunized Native and Human Leukocyte Antigen-DR3-Transgenic Mice and in Graves' Disease Patient Blood.
Degen H; Gavvovidis I; Blankenstein T; Uhland K; Ungerer M
Thyroid; 2021 Jun; 31(6):950-963. PubMed ID: 33208049
[No Abstract] [Full Text] [Related]
3. Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: Therapeutic implications to Graves' disease.
Li CW; Osman R; Menconi F; Concepcion E; Tomer Y
J Autoimmun; 2020 Mar; 108():102402. PubMed ID: 31980336
[TBL] [Abstract][Full Text] [Related]
4. HLA-DR3 transgenic mice immunized with adenovirus encoding the thyrotropin receptor: T cell epitopes and functional analysis of the CD40 Graves' polymorphism.
Pichurin P; Pham N; David CS; Rapoport B; McLachlan SM
Thyroid; 2006 Dec; 16(12):1221-7. PubMed ID: 17199432
[TBL] [Abstract][Full Text] [Related]
5. The role of glutamic or aspartic acid in position four of the epitope binding motif and thyrotropin receptor-extracellular domain epitope selection in Graves' disease.
Inaba H; Martin W; Ardito M; De Groot AS; De Groot LJ
J Clin Endocrinol Metab; 2010 Jun; 95(6):2909-16. PubMed ID: 20392871
[TBL] [Abstract][Full Text] [Related]
6. Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease.
Inaba H; Martin W; De Groot AS; Qin S; De Groot LJ
J Clin Endocrinol Metab; 2006 Jun; 91(6):2286-94. PubMed ID: 16595602
[TBL] [Abstract][Full Text] [Related]
7. A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves' disease.
McLachlan SM; Rapoport B
Endocrine; 2019 Nov; 66(2):137-148. PubMed ID: 31560118
[TBL] [Abstract][Full Text] [Related]
8. Thyrotropin receptor-DNA vaccination of transgenic mice expressing HLA-DR3 or HLA-DQ6b.
Pichurin P; Chen CR; Pichurina O; David C; Rapoport B; McLachlan SM
Thyroid; 2003 Oct; 13(10):911-7. PubMed ID: 14611699
[TBL] [Abstract][Full Text] [Related]
9. Immune response of mice transgenic for human histocompatibility leukocyte Antigen-DR to human thyrotropin receptor-extracellular domain.
Inaba H; Pan D; Shin YH; Martin W; Buchman G; De Groot LJ
Thyroid; 2009 Nov; 19(11):1271-80. PubMed ID: 19725778
[TBL] [Abstract][Full Text] [Related]
10. T-cells recognize multiple epitopes in the human thyrotropin receptor extracellular domain.
Soliman M; Kaplan E; Yanagawa T; Hidaka Y; Fisfalen ME; DeGroot LJ
J Clin Endocrinol Metab; 1995 Mar; 80(3):905-14. PubMed ID: 7533773
[TBL] [Abstract][Full Text] [Related]
11. Epitope recognition in HLA-DR3 transgenic mice immunized to TSH-R protein or peptides.
Inaba H; Moise L; Martin W; De Groot AS; Desrosiers J; Tassone R; Buchman G; Akamizu T; De Groot LJ
Endocrinology; 2013 Jun; 154(6):2234-43. PubMed ID: 23592747
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of experimental Graves' disease by intranasal administration of a T cell epitope of the thyrotropin receptor.
Arima T; Shimojo N; Yamaguchi K; Tomiita M; Kohn LD; Kohno Y
Clin Immunol; 2008 Apr; 127(1):7-13. PubMed ID: 18234558
[TBL] [Abstract][Full Text] [Related]
13. A novel mouse model of Graves' disease: implications for a role of aberrant MHC class II expression in its pathogenesis.
Shimojo N; Arima T; Yamaguchi K; Kikuoka S; Kohn LD; Kohno Y
Int Rev Immunol; 2000; 19(6):619-31. PubMed ID: 11129118
[TBL] [Abstract][Full Text] [Related]
14. Binding of human thyrotropin receptor peptides to a Graves' disease-predisposing human leukocyte antigen class II molecule.
Sawai Y; DeGroot LJ
J Clin Endocrinol Metab; 2000 Mar; 85(3):1176-9. PubMed ID: 10720058
[TBL] [Abstract][Full Text] [Related]
15. Critical Differences between Induced and Spontaneous Mouse Models of Graves' Disease with Implications for Antigen-Specific Immunotherapy in Humans.
Rapoport B; Banuelos B; Aliesky HA; Hartwig Trier N; McLachlan SM
J Immunol; 2016 Dec; 197(12):4560-4568. PubMed ID: 27913646
[TBL] [Abstract][Full Text] [Related]
16. Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves' Disease.
Inaba H; De Groot LJ; Akamizu T
Front Endocrinol (Lausanne); 2016; 7():120. PubMed ID: 27602020
[TBL] [Abstract][Full Text] [Related]
17. The Mechanism of Action of Antigen Processing Independent T Cell Epitopes Designed for Immunotherapy of Autoimmune Diseases.
Shepard ER; Wegner A; Hill EV; Burton BR; Aerts S; Schurgers E; Hoedemaekers B; Ng STH; Streeter HB; Jansson L; Wraith DC
Front Immunol; 2021; 12():654201. PubMed ID: 33936079
[TBL] [Abstract][Full Text] [Related]
18. Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients' T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases?
Soliman M; Kaplan E; Abdel-Latif A; Scherberg N; DeGroot LJ
J Clin Endocrinol Metab; 1995 Aug; 80(8):2312-21. PubMed ID: 7543112
[TBL] [Abstract][Full Text] [Related]
19. Antigen-specific therapy of Graves´ disease and orbitopathy by induction of tolerance.
Ungerer M; Fabbender J; Holthoff HP
Front Biosci (Landmark Ed); 2018 Jun; 23(11):2044-2052. PubMed ID: 29772544
[TBL] [Abstract][Full Text] [Related]
20. Proliferative responses of peripheral blood mononuclear cells from patients with Graves' disease to synthetic peptides epitopes of human thyrotropin receptor.
Okamoto Y; Yanagawa T; Fisfalen ME; DeGroot LJ
Thyroid; 1994; 4(1):37-42. PubMed ID: 7519915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
